Global Performance Evaluation of the AMS CONTINUUM™ Device

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01083199
Recruitment Status : Completed
First Posted : March 9, 2010
Results First Posted : April 12, 2016
Last Update Posted : April 12, 2016
Information provided by (Responsible Party):
American Medical Systems

March 4, 2010
March 9, 2010
March 14, 2016
April 12, 2016
April 12, 2016
October 2007
November 2010   (Final data collection date for primary outcome measure)
  • Successful Device Placement [ Time Frame: During Radical Prostatectomy ]
    Successful Device placement was defined as the establishment of a water-tight anastomosis immediately post-Device placement.
  • Functionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-procedure in Subjects With Successful Device Placement [ Time Frame: 7-21 days post-Device placement ]

    Device removal was first attempted at the 7-day window; if extravasation was noted, the subject returned for a second attempt at the 14-day window. If extravasation was noted at the first and second attempts, the subject could then return for a 3rd and final removal at the 21-day window.

    The following defines the timeframe of each removal attempt:

    • 7-day window (7-10 days post-implant)
    • 14-day window (13-15 days post-implant)
    • 21-day window (19-21 days post-implant)
  • Successful Device Placement [ Time Frame: During Radical Prostatectomy ]
  • Functionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-procedure in Subjects With Successful Device Placement [ Time Frame: 7-21 days post-Device placement ]
Complete list of historical versions of study NCT01083199 on Archive Site
  • Intraoperative/Postoperative Parameters [ Time Frame: At Device placement ]
  • Percentage of Subjects Demonstrating Functionally Adequate Anastomosis at the 1st and 2nd Device Removal Visits [ Time Frame: 7 and 14 days post-Device placement ]
  • Incontinence Rate and I-QOL Score [ Time Frame: Baseline, 6-week, 6 and 12-month evaluations ]
  • Bladder Neck Contracture (BNC) Rate [ Time Frame: Subjects that develop BNC between the scheduled follow-up visits at 6 weeks, 6 and 12 months post-device removal ]
Same as current
Not Provided
Not Provided
Global Performance Evaluation of the AMS CONTINUUM™ Device
Global Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
  1. To evaluate Device performance in providing mucosa to mucosa apposition to facilitate sustainable vesico-urethral anastomosis during a radical prostatectomy procedure.
  2. To assess clinical outcomes of the Device in facilitating the vesico-urethral anastomosis following a radical prostatectomy.

Radical prostatectomy (RP) is the most utilized surgical treatment option for localized prostate cancer due to the multi-focal nature of the disease. RP is most suitable for otherwise healthy men whose cancer is limited to a small area. The RP procedure involves removing the prostate gland, seminal vesicles and nearby lymph nodes. One of the most technically challenging and critical aspects in all of these surgical approaches is reconstruction of the interrupted urinary tract by hand sewing the vesico-urethral anastomosis. This is where the bladder neck is sewn to the urethra after the prostate has been removed.

CONTINUUM™ (study Device) is to be used as part of the RP procedure by facilitating the approximation of the bladder neck and urethral stump. The Device brings together and holds the tissue in place until adequate natural healing of the vesico-urethral anastomosis occurs thereby minimizing extravasation. The Device also provides a conduit for drainage of urine from the bladder out the urethra during tissue healing.

The concept of the CONTINUUM™ device and the feasibility of its operation have been successfully tested in animal and human studies. Pilot clinical studies in the United States (G060095) found that the majority of subjects who received and were discharged with the Device demonstrated a water-tight vesico-urethral anastomosis at the first Device removal visit. Additionally, no unanticipated adverse device effects (UADEs) were reported. The focus of the proposed study is to further verify the performance of the Device in global research centers.

Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Prostate Cancer
Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
Other Name: Anastomosis Device
Experimental: CONTINUUMTM
Intervention: Device: CONTINUUM™
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2010
November 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • All males ≥ 40 years old who are indicated for a radical prostatectomy will be eligible to participate in the study

Exclusion Criteria:

  • If contraindicated for surgery
  • Inability to understand the study or a history of non-compliance with medical advice
  • Unwilling or unable to sign an Informed Consent Form (ICF)
  • A history of:

    1. Recurrent urinary tract infections (UTI)
    2. Recurrent stricture disease
  • Neurological disease with a history of bladder dysfunction (e.g., Parkinson's disease)
  • Uncontrolled insulin-dependent diabetes
  • Chemotherapy within the past 6 months
  • Non-topical steroid use within the past 6 months
  • Allergy to nitinol, nickel, titanium or silicone
Sexes Eligible for Study: Male
40 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Greece,   Spain
Not Provided
Not Provided
American Medical Systems
American Medical Systems
Not Provided
Principal Investigator: Evangelos Liatsikos, MD University of Patras
Principal Investigator: Carlos Hernandez, MD Hospital University Gregorio Maranon
American Medical Systems
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP